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Abstract: Tiagabine hydrochloride (TGB) is a selective gamma-aminobutyric acid (GABA) 
reuptake inhibitor. TGB is effective as an add-on medication in adults and children 12 years 
and older in the treatment of partial seizures. Results of nonrandomized add-on trials with 
TGB show treatment success with seizure reduction of at least 50% in 33% to 46% of patients. 
In newly diagnosed patients with partial epilepsy, TGB monotherapy was as effective as 
carbamazepine. Comedication with TGB elevates the risk of nonconvulsive status (7.8% vs 2.7% 
without TGB). The most common side effects include dizziness/lightheadedness, asthenia/lack 
of energy and somnolence. TGB has no negative effects on cognition; it does not increase the 
risk of fractures or rash. TGB may interfere with color perception. TGB presents an interme-
diate risk for depression in patients with epilepsy (approximately 4%). Regarding the risk of 
overdose, 96–680  mg TGB (mean 224 mg) caused seizures or coma. TGB is an antiepileptic 
drug exhibiting a speciﬁ  c anticonvulsive mechanism of action, the efﬁ  cacy of which is relatively 
low when used in comedication. Critical side effects, such as the induction of nonconvulsive 
status epilepticus, further limit its use.
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Introduction
Tiagabine hydrochloride (TGB) is a selective gamma-aminobutyric acid (GABA) 
reuptake inhibitor. It increases synaptic GABA availability via inhibition of the GAT-1 
GABA transporter on presynaptic neurons and glial cells. By these means, TGB 
prevents the propagation of neuronal impulses that contribute to seizures (Sommerville 
1997). TGB is licensed as an add-on therapy in adults and children 12 years and older 
in the treatment of partial seizures (Bialer et al 2007).
In the era of highly potent newer antiepileptic drugs (AEDs), and in view of current 
competition, TGB has gained the reputation of being a less effective agent in the design 
of combined treatment in focal epilepsies. The following will illustrate advantages and 
limitations of treatment with this substance from a clinical point of view.
Clinically relevant pharmacological aspects
TGB is metabolized by the hepatic cytochrome P450 system, resulting in the formation 
of 5-oxo-TGB, a major urinary metabolite (Sommerville 1997). TGB itself does not 
appear to induce or inhibit hepatic microsomal enzyme systems and hence does not 
interact with oral contraceptives (Harden and Leppik 2006). In vitro studies have 
shown that TGB in plasma is 95% bound to protein. The addition of phenytoin, 
carbamazepine, or phenobarbital does not displace TGB from plasma proteins. 
Valproate causes a small but statistically signiﬁ  cant reduction in binding from 96.3% to 
94.8%. TGB does not displace valproate, phenytoin, carbamazepine, or phenobarbital 
(Gustavson et al 1995; Bialer et al 2007).Neuropsychiatric Disease and Treatment 2008:4(4) 732
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AEDs with enzyme-inducing effects have an impact on 
the pharmacokinetics of TGB. Results of studies indicate 
that the AUC (area under curve) of TGB is signiﬁ  cantly 
lower and the elimination half-life shorter in patients taking 
enzyme-inducing AED than in healthy subjects receiving 
only TGB or in patients taking valproate (Richens et al 1991). 
TGB has no impact on pharmacokinetics of carbamazepine or 
phenytoin, but signiﬁ  cantly alters Cmax and AUC of valproate 
(Gustavson et al 1995).
No systematic information is available on the 
pharmacokinetics of TGB during pregnancy (Tomson and 
Battino 2007).
Anticonvulsant efﬁ  cacy
Monotherapy
In newly diagnosed patients with partial epilepsy, the time 
to withdrawal for any reason, or the time to the ﬁ  rst seizure 
during a 140-week assessment period did not signiﬁ  cantly 
differ between those receiving TGB (n = 42; ﬁ  nal mean dose 
16.2 mg) or carbamazepine (n = 42; ﬁ  nal mean dose 640 mg) 
(Bialer et al 2007).
In patients with chronic partial seizures, a double-blind 
study was conducted to evaluate two regimens (5 or 
10 mg/day weekly increment) for switching current 
medication to TGB monotherapy. 11/20 patients from the 
slow titration group and 12/20 of the fast titration group 
successfully switched to TGB monotherapy (mean dos-
age 13.5 mg and 15.8 mg, respectively). Patients with 
fast titration had greater median percentage reduction of 
seizure frequency. The anticonvulsant effect was main-
tained during the 48 week follow-up evaluation period 
(Bialer et al 2007).
Add-on therapy
The studies performed previous to licensing showed a 
signiﬁ  cant effect of  TGB in reducing the frequency of focal 
and secondary generalized seizures in comparison with 
placebo (Lassen 1994). In a placebo-controlled parallel group 
study (TGB 16, 32, or 56 mg) the two highest doses proved 
to be more signiﬁ  cantly efﬁ  cacious than placebo (Rowan 
et al 1994). The anticonvulsive efﬁ  cacy of the lowest dose 
of 32  mg TGB is improved by elevating the dose (Rowan 
et al 1994; Bauer et al 1995).
Upon comparison of  TGB with other AEDs, no 
difference could be observed in the evaluation of seizure 
freedom, since there was no study to be found in which 
seizure freedom was achieved with TGB (Gazzola 
et al  2007).
In application studies performed following licensing 
of TGB, data analysis proves to be variable. Results of 
nonrandomized add-on studies with TGB show treatment 
success with seizure reduction of at least 50% in 33% to 
35% of patients (Lassen 1994; Crawford et al 2001), with a 
median dose of 35 mg and in 46% of patients with a median 
dose of 46 mg (Lassen 1994).
Jedrzejczak’s (2005) results were the most optimistic. 
71.4% of his patients achieved at least 50% reduction of 
seizure frequency through TGB dosed between 30 and 
50 mg (no mean given). Its anticonvulsive effect was most 
pronounced in comedication with valproate, less with carba-
mazepine, a result we could not reproduce in an own study 
(Bauer et al 2002).
Retrospective studies are less optimistic (Chahem and 
Bauer 2007; Table 1). 13.2 % of patients achieved halving 
of seizure frequency with a mean TGB dose of 32 mg, an 
effect which was observed for a mean treatment duration of 
15.5 months.
Other studies recorded outcome parameters that were 
more difﬁ  cult to compare. A median TGB dose of 30 mg 
over a median period of 3 months recorded a reduction of 
median seizure frequency from 4.5 to 2 per month (Bauer 
et al 2002). Depending on the dose of TGB 40 mg TGB 
yielded 23%–33% seizure reduction (median) over a period 
of 3 months (Arroyo et al 2005). The recording of seizure 
control as a concomitant result of neuropsychological testing 
on comedication with TGB versus topiramate over a period 
of 6 months was also published (Fritz et al 2005). Both 
AEDs had a similar effect in reducing seizure frequency in 
this study.
In the analysis of long-term efﬁ  cacy of AEDs there were 
not any studies in which TGB leads to seizure freedom of at 
least 6 months (Zaccara et al 2006).
In a comparison of combined treatment with various 
AEDs in patients at the Department of Epileptology at 
Bonn University Hospital, the efﬁ  cacy of TGB is more 
easily evaluable, since patients do not vary in their clinical 
characteristics. In retrospectively analyzed data, the efﬁ  cacy 
of TGB is low compared to other AEDs (Table 2).
Anticonvulsive effect and type of seizure
Differentiated analysis of the efﬁ  cacy of TGB on various 
types of seizures uncovers differences. In the evaluation 
of 574 patients, TGB given as comedication reaches 
a median reduction of general seizure frequency from 
4.5 to 2 seizures per month. Complex partial seizures 
were reduced by a median from 2 to 1 per month, simple Neuropsychiatric Disease and Treatment 2008:4(4) 733
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Table 1 Combined treatment with tiagabine: clinical data and treatment results
Clinical data of all patients involved (n = 53)
Sex Men 26 (49%) Women 27 (51%)
Age (last contact) 19–68 years (mean 38 years)
Type of epilepsy All patients with symptomatic/cryptogenic epilepsies
Duration of illness ( n = 37) 1–57 years (mean 24 years)
Additional antiepileptic drugs 1–4 (mean 2.6)
Duration of treatment 1–72 months (mean 12 months)
Patients with  50% seizure reduction (n = 6) or seizure freedom (n = 1)
Maximum dose of tiagabine/day 22.5–45 mg (mean 32.9 mg)
Comedication 1–4 Antiepileptic drugs (mean 2.3)
Duration of efﬁ  cacy Seizure freedom (n = 1) 6 years
Seizure reduction (n = 6) 2–24 months (mean 15.5 months)
Loss of efﬁ  cacy in 3 patients after 18–24 months (mean 20.7)
Patients with  50% seizure reduction (n = 36) or seizure increase (n = 10)
Maximum dose of tiagabine/day 10–60 mg (mean 37.1 mg)
Comedication 1–4 (mean 2.6)
20 with levetiracetam
18 with clobazam
Duration of treatment 1–48 months (mean 10 months)
Side effects (n = 28/53)
Central nervous complaints with dizziness, headache, reduced concentration, affected speech and confusion 18
Sedation 5
Nonconvulsive status epilepticus 5
Gastrointestinal side effects 2
After Chahem and Bauer 2007.
partial seizures from 5 to 3 per month, and generalized 
tonic-clonic seizures from four to one per month (Bauer 
et al 2002).
Jedrzejczak (2005) found a better effect of  TGB in the 
treatment of simple and complex partial seizures than in 
generalized tonic-clonic seizures. Between the fourth and 
16th week of TGB treatment, the number of patients with at 
least 50% seizure reduction increased from 38.9% to 71.4%. 
An increase of  25.2% to 41.1% was observed for generalized 
tonic-clonic seizures.
Seizure-inducing effects
Nonconvulsive focal status epilepticus was a fairly common 
observation after licensing of TGB (Vinton et al 2005). 
Additionally, patients without epilepsy treated with this drug 
experienced ﬁ  rst onset epileptic seizures (Jette et al 2006; 
Haddad et al 2007).
In a retrospective analysis of patients treated in 
Chalfont Epilepsy Center, London between 1997 and 
2000, nonconvulsive status epilepticus was observed 
in 7 out of 90 patients (7.8%) treated with TGB (mean 
dosage 36 mg), and in 32 out of 1165 patients without 
TGB (2.7%) (Koepp et al 2005). In our own retrospective 
study, 5 out of 53 patients with TGB comedication (9.4%) 
experienced nonconvulsive status epilepticus (Chahem 
and Bauer 2007).
General tolerability and overdosage
The most common side effects associated with TGB are 
dizziness/lightheadedness, asthenia/lack of energy, somno-
lence, nausea, nervousness/irritability, tremor, abdominal 
pain, and thinking abnormal/difﬁ  culty with concentration 
or attention (Bialer et al 2007).
In a study concerning 53 patients receiving TGB as 
comedication, side effects occurred in 28 out of 53 patients 
(52.8%) (Table 1). Those patients showing side effects were 
treated with a mean TGB dose of 36.6 mg, while patients who 
did not experience side effects had received an average of 
36.5 mg. As comedication, those patients with sides effects 
had received between 1 and 4 (mean 2.5) additional AEDs Neuropsychiatric Disease and Treatment 2008:4(4) 734
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(14 with Levetiracetam, nine with oxcarbazepine, topiramate 
or clobazam) (Chahem and Bauer 2007).
In a pooled analysis of two studies in newly diagnosed 
patients with partial seizures, there were no detrimental 
effects on cognition after 52 weeks of TGB (20–30 mg) 
in monotherapy; this was similar to the results with 
carbamazepine (400–800 mg) monotherapy (Äikiä et al 
2006). In a combined study, TGB did not show any negative 
inﬂ  uence on neuropsychological performance of the frontal 
lobe (Fritz et al 2005).
In a study on 20 patients with focal epilepsy, TGB 
monotherapy did not have an effect on visual contrast 
sensitivity, but may interfere with colour perception 
(7/17 patients, 41%). There was no evidence of visual ﬁ  eld 
defects (Sorri et al 2005).
TGB presents an intermediate risk for depression in 
patients with epilepsy (about 4%) (Mula and Sander 2007) 
and does not elevate the risk of fractures of patients treated 
with this substance (Vestergard et al 2004). Treatment with 
TGB did not coincide with an elevated risk of developing 
drug-induced rashes (Arif et al 2007). A case report described 
a transient episode of athetosis induced by TGB in a patient 
with symptomatic epilepsy (Tombini et al 2006).
Fifty-seven patients (mean age 30.5 years) with TGB 
overdosage were analyzed. The mean onset and duration 
of symptoms were 1.3 hours and 9.1 hours, respectively. 
The mean dose of patients with and without symptoms was 
102 mg and 10 mg, respectively. The mean dose for patients 
experiencing seizures was 224 mg (range 96–680 mg), and 
the mean dose for patients with respiratory depression and 
coma was 270 mg (range 96–680 mg) (Cantrell et al 2004; 
Spiller et al 2005). Acute treatment of seizures is with 
benzodiazepines. In addition, daily dosage of TGB has to 
be reduced.
Discussion
The main indication for prescription of  TGB is the add-on 
treatment of patients with previously pharmacoresistant 
focal epilepsies for which this agent is licensed. Even if its 
mechanism of action may suggest an additive efﬁ  ciency of 
AED of other action mechanisms, TGB in its clinical use 
has not been established as an agent of ﬁ  rst or second choice 
(Bauer and Reuber 2003). A signiﬁ  cant contributing factor 
to this fact is the lack of efﬁ  cacy in achievement of seizure 
freedom – the ﬁ  nal item in the assessment of an AED (Bauer 
et al 2008). Despite the low quota of seizure freedom with 
Table 2 Tiagabine add-on treatment of focal epilepsies in adults
Reference Patients
(total number)
Tiagabine
dosage
Study
period
Aim of study Study outcome
(if others than
seizure reduction)
Seizure outcome
Bauer et al 
1995
17 12–64 mg
(mean not given)
At least 6 
months
Seizure reduction  50% 
vs baseline
Not applicable 50% Seizure reduction
TGB 12–24 mg: 8/17 (47%)
TGB 26–36 mg: 5/15 (33%)
TGB 38–48 mg: 4/8 (50%)
TGB 52–64 mg: 2/3
Bauer et al 
2002
574 29.1 mg (mean; 
range not given)
94.9 ± 42.7 
days
Mean seizure reduction Not applicable Decrease of total seizure 
frequency from 4.5 to 2.0 
seizures/month
Seizure free at the end of 
study period: 12.3%
Arroyo et al 
2005
243 40 mg 12 weeks Comparison bid vs tid Fewer patients with 
b.i.d completed the 
study
Median percentage 
decrease of all seizure types
33.4% (bid)
23.8% (tid), ns
Jedrzejczak 
2005
330 30–50 mg
(mean not given)
16 weeks Seizure reduction  50% 
vs baseline
Seizure control was 
signiﬁ  cantly better 
with VPA
50% Seizure reduction
All patients: 71.4%
Chahem and 
Bauer 2007
53 10–60 mg
(mean 36.5 mg)
1–7 months
(mean 12 
months)
Seizure reduction  50% 
vs baseline
50% Seizure reduction:
7/53 (13.2%)
including 1 patient with 
seizure control for 6 years
Abbreviations: TGB, tiagabine; bid, twice daily; ns, not signiﬁ  cant; tid, three times daily; VPA, valproate.Neuropsychiatric Disease and Treatment 2008:4(4) 735
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Table 3 Efﬁ  cacy of add-on treatment in focal epilepsy
Topiramate Pregabalin Felbamate Tiagabine Sulthiame
Number of patients
(men/women)
98 (42/56) 98 (55/43) 41 (25/16) 53 (26/27) 28 (14/14)
Age in years (mean) 3–70.6 (33.6) 15–70 (37) 8–54 (29) 19–68 (38) 18–57 (32.6)
Duration of epilepsy in 
years (mean)
1–55.5 (16.2) Not given 5–40 (25) 1–57 (24) 9–48 (24.9)
Additional AED (mean) 0–5 (1.7) 1–5 (2.7) 0–6 (2.4) 1–4 (2.6) 0–5 (2.5)
Duration (in years) of 
treatment with the AED 
evaluated (mean)
87 patients with complete 
follow-up 0.5–24 months (13.6)
11 patients without complete 
follow-up 8.9–17.6 months (14.4)
32  3 months
34: 3–12 months
32: 12 months
1–72 months (18) 1–72 months (12) 1–156 months (30.6)
Reduction of seizure 
frequency by at least 50% 
(without complete seizure 
control)
14 (14.2%) 8/94* (8.5%) 8/41 (19.5%) 6/53 (11.3%) 5/28 (17.8%)
Complete seizure control 14 (14.3%) − 1/41 (2.4%), for 6 years 1/53 (1.8%), for
6 years
−
After Bauer and Ruocco 2006; Chahem and Bauer 2007; Beerlage and Bauer 2007.
*no follow-up in 4 patients.
Abbreviation: AED, antiepileptic drug.
other AED in comedication of chronic focal epilepsies, eg, 
for levetiracetam 6.6% (Bauer et al 2006); the success of 
each patient does inﬂ  uence the intuitive ranking of AED by 
doctor and patient alike. The low efﬁ  cacy of TGB in this 
treatment phase becomes particularly obvious in the most 
recent study by Gazzolla et al (2007). In this study, seizure 
freedom analyses achieved during clinical trials included 
both patients who completed the trial, and those who dropped 
out prior to completion. No study that proved this for TGB 
was found. For other AEDs, rates of seizure freedom were 
0.8% (trial completed) versus 0.7% (drop out) (lamotrigine), 
2.6% versus 12% (oxcarbazepine), 3.9%–7.1% versus 
3.6%–6.4% (levetiracetam), 1.3%–1.4% versus 3.0%–7.9% 
(pregabalin), and 3.0%–6.0% (zonisamide).
Even upon comparison with other AEDs of third choice, 
such as felbamate, sulthiame or pregabalin, the successes of 
TGB seem comparatively low (Table 3). Upon comparison 
with highly potent agents such as topiramate, the substance 
cannot reach comparable results, even if the ﬁ  ndings in a 
neuropsychologically orientated study may suggest this 
(Fritz et al 2005).
Tolerability remains a problematic issue. In comparison 
with felbamate and sulthiame, TGB appeared to have the 
highest rate of side effects and the lowest anticonvulsant 
effect (Table 3). The induction of nonconvulsive status 
epilepticus has signiﬁ  cantly contributed to TGB’s bad 
reputation (Bauer 1996; Koepp et al 2005; Chahem and 
Bauer 2007).
Once the decision to treat with this agent has been made, 
TGB must be slowly introduced with a dose elevation of 
5 mg per week. Suitably high doses should be aimed for (at 
least 45–60 mg), since dose elevation has been proven to 
enhance its effect. TGB should be taken three times a day, 
which appears to be most efﬁ  cient from an anticonvulsive 
point of view (Arroyo et al 2005; Table 2). In combination 
with carbamazepine, our experience shows that cerebellar 
side effects must be expected when both agents are given 
in higher doses. We cannot identify a considerable advan-
tage or disadvantage in the comedication of TGB with a 
particular AED.
The results of treatment of newly diagnosed epilepsies 
with TGB in monotherapy are more optimistic. In this 
context TGB appeared to be as efﬁ  cacious as carbamazepine. 
Currently, TGB is not licensed for this indication.
In summary, TGB is an AED which exerts a speciﬁ  c 
mechanism of action with an efﬁ  cacy which is relatively 
low in comedication. Critical side effects such as the 
induction of non-convulsive status epilepticus limit its 
use. Possibly the establishment of its licencing for mono-
therapy is a chance to give this AED a broader range of 
prescription.
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